# Ind-Swift Laboratories share price today (Ind-Swift Laboratories Ltd, NSE: INDSWFTLAB) > Ind-Swift Laboratories share price today: ₹336.75 at the NSE close on 18 November 2026, up 234.9% in a year. Ind-Swift Laboratories (NSE: INDSWFTLAB) is worth ₹2,931 crore, trades at a P/E of 34.8 and has closed between ₹90.37 and ₹407.70 over the past 52 weeks. > Ind-Swift Laboratories Ltd's share price has risen faster than its earnings: +234.9% in a year, against −88.0% for earnings per share. INDSWFTLAB · Pharma - API · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Getting worse, from fewer quarters than usual - Price: ₹336.75 (+234.9% in a year) - P/E: 34.8× (higher than 88% of the last 8.1 years) - Revenue (Sep 2026): ₹240 Cr (+50.9% on a year ago) - Profit (Sep 2026): ₹34.0 Cr (+325.0% on a year ago) - Operating margin: 18.8% (+14.4 points on a year ago) - ROCE: 5%, FY26 - Profit that came in as cash: −36%, last 3 years The main question: profits are rising, but only −36% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Ind-Swift Laboratories share price today? Ind-Swift Laboratories Ltd's share price was ₹336.75 at the close on 18 November 2026. It has been rising for 40 weeks. That is 31.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹90 and ₹408, and at that close it sat 78% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running. Over the last 11 years the share price moved +838% while the NIFTY 500 moved +306%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 8 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Ind-Swift Laboratories this quarter? Three changes stood out: best operating margin in 12 quarters, revenue up on a year earlier for 6 quarters in a row and highest quarterly revenue in 10 quarters. 1. Best operating margin in 12 quarters Operating margin was 19% in the September 2026 quarter, against 4.7% a year earlier. Why: Margins rose because raw material costs took a smaller share of sales, helped by a better product mix and more output spread over fixed costs. Next results: check whether the December quarter margin reaches the 19 to 20 percent management expects and the full year stays above 19 percent. From the earnings call on 4 Nov 2026. 2. Revenue up on a year earlier for 6 quarters in a row In the September 2026 quarter revenue was ₹240 crore, +50.9% on a year earlier. Why: Sales rose because the company sold more of its own brand medicines, led by Atorva-Ezetimibe, and added registrations in emerging markets. Next results: check whether Ibuprofen brings in the expected Rs 20 crore in the December quarter. From the earnings call on 4 Nov 2026. 3. Highest quarterly revenue in 10 quarters Revenue of ₹240 crore in the September 2026 quarter is the highest of the last 10 quarters. Why: Sales reached a new high because contract work for Viatris-linked medicines increased. Next results: check whether second half sales are enough for the full year comfort management mentioned, especially from Ibuprofen. From the earnings call on 4 Nov 2026. ## What are Ind-Swift Laboratories' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Ind-Swift Laboratories reported revenue of ₹240 crore, up 50.9% from ₹159 crore a year earlier, and a profit of ₹34.0 crore, up 325.0% from ₹8.00 crore. ### Ind-Swift Laboratories results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹240 crore | ₹159 crore | +50.9% | | Profit | ₹34.0 crore | ₹8.00 crore | +325.0% | | Earnings per share | ₹3.94 | ₹0.98 | +302.0% | | Operating margin | 18.8% | 4.4% | +14.4 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Ind-Swift Laboratories' management discussed these results on a call held on 4 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Ind-Swift Laboratories share price history? Ind-Swift Laboratories closed at ₹336.75 on 18 November 2026, up 234.9% from ₹100.56 a year earlier (21 November 2025) and up 356.0% over five years. Its highest weekly close since February 2016 was ₹407.70 on 28 September 2026. ### Ind-Swift Laboratories share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹363.20 | −7.3% | | 1 month ago · 19 Oct 2026 | ₹351.90 | −4.3% | | 6 months ago · 15 May 2026 | ₹133.89 | +151.5% | | 1 year ago · 21 Nov 2025 | ₹100.56 | +234.9% | | 3 years ago · 17 Nov 2023 | ₹94.10 | +257.9% | | 5 years ago · 18 Nov 2021 | ₹73.85 | +356.0% | | 10 years ago · 18 Nov 2016 | ₹35.50 | +848.6% | | Earliest weekly close in our records · 26 Feb 2016 | ₹35.90 | +838.0% | | Highest weekly close since February 2016, also the 52-week high · 28 Sep 2026 | ₹407.70 | −17.4% | | Lowest weekly close since February 2016 · 6 Mar 2020 | ₹16.10 | +1,991.6% | | 52-week low (weekly close) · 9 Jan 2026 | ₹90.37 | +272.6% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (569 weekly closes from 26 February 2016 to 18 November 2026.) ## What is the latest news on Ind-Swift Laboratories? 18 Nov 2026: Ind-Swift Laboratories closed at ₹336.75, down 7.3% on the week and down 4.3% on the month. 4 Nov 2026: Ind-Swift Laboratories held its results call for July to September 2026. Management guided: FY27 revenue growth above 50% reiterated as comfortable with delivery weighted to H2. ### Earlier - Results for July to September 2026: Revenue up 50.9% and profit up 325.0% on a year earlier. ## What dividend does Ind-Swift Laboratories pay? Ind-Swift Laboratories has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Ind-Swift Laboratories Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Ind-Swift Laboratories management say on the latest results call? On the call for July to September 2026, held on 4 November 2026, Ind-Swift Laboratories' management guided: FY27 revenue growth above 50% reiterated as comfortable with delivery weighted to H2. > “We think the orders are in hand, the raw materials are in place and the production facility is equipped. Therefore, we just need to deliver; we just need to manufacture and deliver.” > Management, on the call for July to September 2026 ### What management guided - CDMO incremental revenue ₹100-130 crore in FY27 and ₹200-220 crore over 2 years. - Ibuprofen revenue ₹20 crore in Q3 and ₹20-25 crore in Q4; two more customers for same molecules eyed for Q4 sign-off. - Medium-term revenue yearly growth 20-25% to cross ₹1,500 crore by FY30 with operating profit expansion 200-300 basis points. - More than 300 registrations in FY27; 11 molecules for 2028-29 plus 2 for 2029-30 with no new molecule in FY28. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4316/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 4 November 2026.) ## What to watch in Ind-Swift Laboratories' next results? When Ind-Swift Laboratories reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Q3 margin delivery at the flagged band with blended improvement - per management lift commentary. Management raised each of these on the latest results call. - Q3 margin delivery at the flagged band with blended improvement - per management lift commentary. - European variation clearance for Clarithromycin with batch start - per launch-awaited commentary. - H2 revenue coverage for full-year comfort with second-half Ibuprofen scale - per orders-in-hand claim. ## Which stock lists is Ind-Swift Laboratories on? Ind-Swift Laboratories is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market value: ₹2,886 crore](https://www.sectoralpha.in/momentum-stocks-india) - [Pharma stocks Market value: ₹2,886 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Ind-Swift Laboratories profitable? Ind-Swift Laboratories Ltd earned ₹34.0 Cr of net profit in the Sep 2026 quarter, +325.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹43.0 Cr. The Sep 2026 quarter's profit is 14.2% of that quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹43.0 Cr (−82.8% on the year before). Why profit moved: revenue changed +50.9% on a year earlier and the margin moved +14.4 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +136.5% and revenue +29.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Ind-Swift Laboratories make, and is it growing? Ind-Swift Laboratories Ltd reported ₹240 Cr of revenue in the Sep 2026 quarter, +50.9% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown −0.1% a year on average. The last full year, FY26, came in at ₹649 Cr. The last four reported quarters add to ₹752 Cr. FY26 revenue was ₹649 Cr, +13.1% on the year before. Recent pace: the last four quarters grew +29.0% on average, against −0.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +29.9%, against −6.6% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −64.1%, against −59.6% a year (rolling over). ## How much of every ₹100 of sales does Ind-Swift Laboratories keep? Ind-Swift Laboratories Ltd's operating margin was 18.8% in the Sep 2026 quarter, 14.4 percentage points higher than the same quarter a year ago. Across 13 years it has been between −1.2% and 20.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +14.2 percentage points on the year while gross margin changed +4.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Ind-Swift Laboratories' profit turning into cash? Over the last 3 years Ind-Swift Laboratories Ltd's operations used more cash than they brought in, so cash conversion was −36%, a gap worth watching. In FY26 its operations used ₹68.0 Cr of cash, against ₹43.0 Cr of profit. After ₹88.0 Cr of spending on assets, free cash was −₹156 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −36% of profit came in as cash: the cash cycle got 253 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: the bigger use of cash is spending on new assets, at 2.1× depreciation over three years. The next section checks what that spending is building. ## Where does Ind-Swift Laboratories' cash go? Ind-Swift Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 114 days in FY26, down from 367 days in FY21. It spent ₹225 Cr on assets over the last 3 years. Customers take 112 days to pay, and stock sits for 187 days on average. At FY26 sales of ₹649 Cr, each day of that cycle ties up about ₹1.8 Cr, so roughly ₹203 Cr is tied up in the business at any time. FY26: customers took 112 days to pay and stock sat for 187 days, about 6.2 months of sales sitting as stock, for a full cycle of 114 days, shorter than FY21's 367. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 187 days. Customers pay about 112 days after that. Suppliers are paid at 185 days. Together that makes the 114-day cycle. Spending on assets: ₹225 Cr over the last 3 years, against ₹108 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹12.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Ind-Swift Laboratories' P/E ratio, and how does it compare with its own history? Ind-Swift Laboratories Ltd's P/E is 34.8×, near the high end of its own history: higher than 88% of past readings. Its usual P/E (the middle reading) is 16.6×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹9.69. Why the multiple is where it is: over the past year earnings per share moved −88.0% while the price moved +234.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +35.5% a year; about +19.4% a year came from earnings growth and about +16.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 277% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Ind-Swift Laboratories business getting better or worse? Ind-Swift Laboratories Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −64.1% in the latest quarter, against +1039.5% at its best in 12 quarters, with ROCE steady at 5.0% (four quarters to FY26). This is based on 9 quarters of 4 measures, with some gaps. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Ind-Swift Laboratories earn on its capital? Ind-Swift Laboratories Ltd earned a ROCE of 5% in FY26. That is up from a low of 0% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 6.6% net margin and 0.39× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.6% net margin × 0.39× asset turnover × 1.21× leverage (assets divided by equity) ≈ 3.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 277% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Ind-Swift Laboratories have too much debt? Ind-Swift Laboratories Ltd had ₹18.0 Cr of borrowings against ₹1,384 Cr of equity in FY26, so its debt is 0.01× its equity. Its operating profit is 47 times its interest bill. Over 5 years borrowings went from ₹1,005 Cr to ₹18.0 Cr. Over the last 3 of those years it spent ₹225 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 277% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Ind-Swift Laboratories shareholding pattern? Foreign institutions raised their stake in Ind-Swift Laboratories Ltd by 10.3 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 10.8% of the company. Promoters moved +0.9 points over the same period, to 42.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +10.3 points over 8 quarters, to 10.8%; Promoters: +0.9 points over 8 quarters, to 42.9%; Domestic institutions: −0.7 points over 8 quarters, to 0.2%. Why the owners changed: foreign institutions drove it (+10.3 points), together with promoters (+0.9 points). They raised their stake step by step. ## How far is Ind-Swift Laboratories from balance-sheet trouble? For Ind-Swift Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Ind-Swift Laboratories rank in its industry? 49.9 out of 100, rank 7 of 14 in Pharma - API, with 82% of the evidence available. Ind-Swift Laboratories Ltd scores 49.9 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 7. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.8 + 8.3 + 7.2 + 14.6 = 49.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Ind-Swift Laboratories compared with? Ind-Swift Laboratories ranks 7 of 14 Pharma - API companies on the 4-Factor Sector Score, with 49.9 out of 100. 1. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Most evidence points up · 90% evidence 66.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.5/35 · Revenue 36.8% · Profit 32.8% · Operating margin change 0 points · 100% evidence Capital efficiency 12.4/25 · ROCE 15% (year to Mar 2026) · Operating margin 14.1% · 100% evidence Valuation 11.6/20 · P/E 36× · PEG n/a · 50% evidence Relative strength 17.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.1% · Strength vs NIFTY 500 (same reading) 29.8% · 1 year 38.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.5 + 12.4 + 11.6 + 17 = 66.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Most evidence points up · 90% evidence 66.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 15.1% · Profit 15.1% · Operating margin change 3 points · 100% evidence Capital efficiency 13.9/25 · ROCE 12% (year to Mar 2026) · Operating margin 16.3% · 100% evidence Valuation 12.4/20 · P/E 20.2× · PEG n/a · 50% evidence Relative strength 17.3/20 · Strength vs its industry (price vs its 52-week average, weekly) 10.1% · Strength vs NIFTY 500 (same reading) 24.1% · 1 year 14.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.7 + 13.9 + 12.4 + 17.3 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.8/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 30.2% · 76% evidence Valuation 9.0/20 · P/E 37.7× · PEG n/a · 15% evidence Relative strength 7.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -4.1% · Strength vs NIFTY 500 (same reading) 6% · 1 year 33.3% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.8 + 16.4 + 9 + 7.1 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 90% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.9/25 · ROCE 14.9% (year to Mar 2026) · Operating margin 9.2% · 100% evidence Valuation 14.2/20 · P/E 16.7× · PEG n/a · 50% evidence Relative strength 7.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -11.6% · Strength vs NIFTY 500 (same reading) -0.2% · 1 year 0% · 100% evidence · 9 of 12 weeks ahead Exact sum: 24.5 + 13.9 + 14.2 + 7.1 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · quiet · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% (year to Mar 2026) · Operating margin 21.9% · 76% evidence Valuation 8.0/20 · P/E 37.4× · PEG n/a · 50% evidence Relative strength 10.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 3.1% · 1 year 8.5% · 25% evidence · 4 of 12 weeks ahead Exact sum: 19.4 + 18.4 + 8 + 10.2 = 56 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans up · 66% evidence 53.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 34.1% · Profit 100% · Operating margin change 11.8 points · 74% evidence Capital efficiency 7.0/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 7.3% · 100% evidence Valuation 6.7/20 · P/E 32.6× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 55.1% · 1 year 106.8% · 25% evidence · 11 of 12 weeks ahead Exact sum: 27.9 + 7 + 6.7 + 12.3 = 53.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Ind-Swift Laboratories Ltd this page INDSWFTLAB · leader · Evidence leans down · 82% evidence 49.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% (year to Mar 2026) · Operating margin 18.8% · 76% evidence Valuation 7.2/20 · P/E 34.8× · PEG n/a · 50% evidence Relative strength 14.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 59.5% · Strength vs NIFTY 500 (same reading) 71.3% · 1 year 234.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.8 + 8.3 + 7.2 + 14.6 = 49.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · leader · Evidence leans down · 75% evidence 49.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.3/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% (year to Mar 2026) · Operating margin 22.1% · 100% evidence Valuation 7.6/20 · P/E 35.8× · PEG n/a · 50% evidence Relative strength 11.8/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 28.3% · 1 year 46% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.3 + 12.4 + 7.6 + 11.8 = 49.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · quiet · Evidence leans down · 90% evidence 47.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.9/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 18.9/25 · ROCE 22.7% (year to Mar 2026) · Operating margin 21% · 100% evidence Valuation 11.0/20 · P/E 30.4× · PEG n/a · 50% evidence Relative strength 4.7/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 0.9% · 1 year 3.3% · 100% evidence · 5 of 12 weeks ahead Exact sum: 12.9 + 18.9 + 11 + 4.7 = 47.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans down · 83% evidence 47.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.9/35 · Revenue 15% · Profit -11.2% · Operating margin change -12.1 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.1% (year to Mar 2026) · Operating margin 37.4% · 100% evidence Valuation 8.7/20 · P/E 95.2× · PEG n/a · 15% evidence Relative strength 10.4/20 · Strength vs its industry (price vs its 52-week average, weekly) -8.5% · Strength vs NIFTY 500 (same reading) 3.1% · 1 year -12.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 9.9 + 18 + 8.7 + 10.4 = 47 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · basing · Evidence leans down · 68% evidence 44.7 out of 100 Growth Capital Valuation Relative 12. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 68% evidence 40.4 out of 100 Growth Capital Valuation Relative 13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · quiet · Evidence leans down · 66% evidence 39.7 out of 100 Growth Capital Valuation Relative 14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 31.5 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Ind-Swift Laboratories in size? Ind-Swift Laboratories is the 7th largest of 14 Pharma - API companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Senores Pharmaceuticals, Gujarat Themis Biosyn and Aarti Drugs. Just below it: Beta Drugs, Jagsonpal Pharmaceuticals and Fermenta Biotech. ### Pharma - API companies close in size 1. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) ₹5,031 crore 2. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) ₹4,722 crore 3. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) ₹4,616 crore 4. Ind-Swift Laboratories Ltd ₹2,929 crore 5. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,004 crore 6. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,376 crore 7. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) ₹1,343 crore [All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies) ### Companies close in size in other industries 1. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) ₹2,942 crore · Hospitals 2. [Marathon Nextgen Realty Ltd](https://www.sectoralpha.in/stocks/marathon-nextgen-realty-ltd) ₹2,940 crore · Realty - Regional 3. Ind-Swift Laboratories Ltd ₹2,929 crore 4. [HLE Glascoat Ltd](https://www.sectoralpha.in/stocks/hle-glascoat-ltd) ₹2,918 crore · Glass - Others 5. [Bharat Bijlee Ltd](https://www.sectoralpha.in/stocks/bharat-bijlee-ltd) ₹2,915 crore · Capital Goods - Transformers ## What else do people ask about Ind-Swift Laboratories? ### What is Ind-Swift Laboratories's share price today? Ind-Swift Laboratories Ltd's share price is ₹336.75, +234.9% over the past year. The whole company is worth ₹2,931 Cr on the market. In the last 52 weeks it traded between ₹90 to ₹408; today it is 78% of the way up from the low, 31.7% above its 200-day average (as of 18 November 2026). ### What were Ind-Swift Laboratories's latest quarterly results? Ind-Swift Laboratories Ltd reported revenue of ₹240 Cr and net profit of ₹34.0 Cr for the Sep 2026 quarter. Revenue rose 50.9% and profit rose 325.0% compared with a year earlier. Earnings per share were ₹3.94. The operating margin was 18.8%, 14.4 percentage points higher than a year earlier (as of 18 November 2026). ### What is Ind-Swift Laboratories's market cap? Ind-Swift Laboratories Ltd's market capitalisation is ₹2,931 Cr at a share price of ₹336.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Ind-Swift Laboratories performing? Ind-Swift Laboratories Ltd's share price has been rising for 40 weeks. In its latest quarter, revenue rose 50.9% and profit rose 325.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 2 weeks running (as of 18 November 2026). ### Will Ind-Swift Laboratories's share price go up? This page does not forecast Ind-Swift Laboratories Ltd's share price. What it shows instead: the share price is ₹336.75, and it has been rising for 40 weeks. Its P/E of 34.8× is higher than 88% of its own last 8 years (as of 18 November 2026). ### Who owns Ind-Swift Laboratories? Promoters own 42.9% of Ind-Swift Laboratories Ltd, foreign institutions 10.8%, domestic institutions 0.2% and the public 46.1% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 10.3 percentage points over 8 quarters (as of 18 November 2026). ### Where is Ind-Swift Laboratories in its business cycle? Ind-Swift Laboratories Ltd's FY26 operating margin was 7.2%, against a 13-year range of −1.2% to 20.5%. The latest quarter was 18.8%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Ind-Swift Laboratories story? The main question: profits are rising, but only −36% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Ind-Swift Laboratories a stock worth studying right now? What the numbers show: Ind-Swift Laboratories Ltd's share price has risen faster than its earnings: +234.9% in a year, against −88.0% for earnings per share. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Ind-Swift Laboratories share price forecast for 2026? What management itself guided: FY27 revenue growth above 50% reiterated as comfortable with delivery weighted to H2. ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.